These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 788762)

  • 1. Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes.
    Giovarelli M; Comoglio PM; Forni G
    Br J Cancer; 1976 Sep; 34(3):233-8. PubMed ID: 788762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. II. Dynamic changes during tumor progression.
    Wang WC; Berczi I; Hoffmann EG; Sehon AH
    Int J Cancer; 1980 Apr; 25(4):493-501. PubMed ID: 6246008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
    Wang KC; Berczi I; Sehon AH
    Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1441-8. PubMed ID: 15034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
    Platica M; Bojko C; Steiner G; Hollander VP
    Cancer Res; 1980 Jul; 40(7):2229-33. PubMed ID: 6248200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
    Haubeck HD; Kölsch E
    Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological enhancement of tumor growth by syngeneic thymus-derived lymphocytes.
    Umiel T; Trainin N
    Transplantation; 1974 Sep; 18(3):244-50. PubMed ID: 4608685
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
    Nio Y; Ohgaki K; Tobe T
    J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of MOPC 104E by T cells and growth factors induced by C. parvum stimulation.
    Shrestha K; Hiramoto RN; Ghanta VK
    Int J Cancer; 1984 Jun; 33(6):845-50. PubMed ID: 6610653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of cell-surface antigenicity of the mouse plasmacytoma. I. Immunologic characterization of surface antigens masked during successive transplantations.
    Ono S; Natsu-ume S; Migita S
    J Natl Cancer Inst; 1975 Sep; 55(3):569-77. PubMed ID: 51090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression and enhancement of allografted tumour.
    Yutoku M; Seno H; Matsuoka Y; Kitagawa M
    Immunology; 1974 Mar; 26(3):623-37. PubMed ID: 4854531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
    Kleinman R; Dray S
    Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization.
    Mokyr MB; Hengst JC; Przepiorka D; Dray S
    Cancer Res; 1979 Oct; 39(10):3928-34. PubMed ID: 157800
    [No Abstract]   [Full Text] [Related]  

  • 19. Transplantation immunity to simian virus 40-transformed cells in tumor-bearing mice. II. Evidence for macrophage participation at the effector level of tumor cell rejection.
    Zarling JM; Tevethia SS
    J Natl Cancer Inst; 1973 Jan; 50(1):149-57. PubMed ID: 4348219
    [No Abstract]   [Full Text] [Related]  

  • 20. The haemopoietic and immunogenic capacities of living hybrid bone marrow cells tested in tumour allograft rejection.
    Kerckhaert JA; Hofhuis FM; Willers JM
    Immunology; 1975 Apr; 28(4):693-702. PubMed ID: 1150311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.